In this review:
Survival longer with double vs. single SCT in newly diagnosed MM
Response-adapted lenalidomide maintenance in transplant-eligible MM
Bortezomib- vs. lenalidomidebased induction in high-risk cytogenetic MM
Antibiotic use in MM patients
Lenalidomide maintenance improves MM outcomes irrespective of cytogenetic risk
MRD in MM
Daratumumab, bortezomib, melphalan and prednisone in newly diagnosed MM
Curative strategy for high-risk smouldering MM
Adding busulfan to melphalan for MM
Antibody drug conjugate against BCMA
Please login below to download this issue (PDF)